Bevacizumab is an effective treatment for symptomatic cerebral necrosis after carbon ion therapy for recurrent intracranial malignant tumours: A case report

• DOI: 10.3892/mco.2022.2547
• Publication Date: 2022-05-19T08:34:51Z
• Authors: Ruifeng Liu; Hongtao Luo; Qiuning Zhang; Shilong Sun; Zhiqiang Liu; Xiaohu Wang; Yichao Geng; Xueshan Zhao
• Keywords: 03 medical and health sciences; 0302 clinical medicine; Case Report

Carbon ion therapy (CIT) is a form of particle therapy, which not only spares normal tissues but may also improve local control recurrent intracranial tumours. Cerebral radiation necrosis (RN) one the most serious adverse reactions brain tumours following reirradiation, lead to neurological decline or even death. Bevacizumab an anti‑vascular endothelial growth factor antibody, has been used treat symptomatic RN. However, studies on bevacizumab for treatment CIT‑induced RN are sparse. The present study described two cases that were successfully treated with CIT malignant tumours, chondrosarcoma in right cavernous sinus and anaplastic meningioma frontal lobe, enrolled clinical trial CIT. Both intravenously when deterioration appeared be was observed. Just before CIT, enhanced magnetic resonance imaging (MRI) performed each case confirm tumour recurrence. exhibited symptoms, as well MRI, at 12‑month intervals first underwent positron emission tomography/computed tomography no increase fluorodeoxyglucose uptake lesion areas. diagnosed having began intravenous administration four cycles 5 mg/kg biweekly. patients responded well, rapid marked improvements symptoms. No progression observed 24 months after In conclusion, revealed exert effects Notably, should administered specifically based aim treating necrosis, long‑term prophylactic applications recommended.